Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.123
Bottom line from this bounded source set
The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.12
Reviewed study record
Early pharmacology trials in healthy adults
Design
Two blinded randomized placebo-controlled studies assessed pharmacokinetics and hormone responses over 28 and 49 days.1
Population
Participants were healthy adults aged 21–61; the abstract does not state their total number.1
Outcomes reported
Growth hormone and IGF-I concentrations increased for several days. The report recorded no serious adverse reactions.1
Limitations
Short-term hormone changes are surrogate measurements. No serious reactions in these studies does not establish safety over longer exposure or in other populations.1
Reviewed study record
Growth-hormone pulsatility
Design
A before-and-after physiology study measured overnight hormone secretion before and one week after exposure.2
Population
The participants were healthy men aged 20–40; the abstract does not state their total number.2
Outcomes reported
Mean and trough growth hormone levels and IGF-I increased, while pulse frequency and magnitude were unchanged.2
Limitations
The report describes an albumin-binding preparation and physiological endpoints. It does not establish improvement in a clinical condition or comparative long-term safety.2
Reviewed study record
Exploratory serum-protein biomarkers
Design
A before-and-after serum analysis compared samples before exposure and one week afterward.3
Population
Eleven healthy young adult men contributed samples.3
Outcomes reported
The authors identified changes in several protein spots and an association between one spot and IGF-I levels. These were proposed biomarkers.3
Limitations
This small exploratory analysis measured proteins, not clinical benefit. The selected abstract alone does not establish participant overlap; the companion FDA assessment supplies that context.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2005-1536. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2006-1702. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.ghir.2009.03.001. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗